Entry into the Japanese pharmaceutical giant Daiichi Sankyo Turkey

More interested in innovative medicines Japanese Daiichi Sankyo, has opened offices in Turkey. Company as the first thing he wanted to take osteoporosis medication in the market unveiled

ISTANBUL - Japanese pharmaceutical company Daiichi Sankyo, which will open Turkey office. Daiichi Sankyo'dan in the written description, Daiichi Sankyo Pharmaceutical Trading Ltd. All rights reserved. activities under the name of the company will be the center of Istanbul and Turkey to market Evista (Raloxifen) will enter the osteoporosis drug, he said.

Noted that the new institutions in Turkey's strategic management of Japanese pharmaceutical companies in Europe will take place in central Germany, the Munich head office, Turkey as well as offices in Germany, France, Britain, Spain and Italy all major western European pharmaceutical market is also centrally recorded.

Cardiology is growing in
, Noted that companies in the field of cardiology in the medium term growth target phrase was significant. Chairman Reinhard Bauer de Daiichi Sankyo Europe, issues related to assessments, the global pharmaceutical market in Turkey to increase the prevalence of a very important step for them said. In this way, until the year 2015 in Europe, leading pharmaceutical companies take its place among the goals one step closer to that expressed the Bauer, a multinational pharmaceutical company located in Turkey's Daiichi Sankyo'yu important factor affecting one of the market, and Turkey in the necessity of representation have been made . According to the information, research and sales of innovative medicines, pharmaceutical companies are interested in a Daiichi Sankyo in 2005, and Daiichi Sankyo is to combine traditional Japanese companies.

Turnover of 5.5 billion dollars
The company achieved a turnover of 5.5 billion Euro in 2007 in Tokyo center, the European center in Munich. With offices in 11 European countries with Daiichi Sankyo, research activities heart / circulatory, hematology, diabetes, antibiotics and cancer areas is getting intense.